Shares of InMed Pharmaceuticals Inc. (INM) are up nearly 350% at $0.66 in premarket trading today after the company confirmed that its investigational drug INM-901 as an oral formulation will be utilized in its development programs for Alzheimer's disease.
INM-901, a proprietary small molecule drug candidate currently in preclinical testing, has shown in studies that it can be administered orally and achieve therapeutic brain levels similar to those attained via intraperitoneal (IP) injection. IP injection is a standard method used in preclinical research for neurodegenerative diseases.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.